A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

NCT01141569 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions

DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)